It was just a tiny speck, a cthat researchers had marked with a fluorescent green dye. But it was the very first cell of what would grow to be a melanoma, the deadliest form of skin cancer. Never before had researchers captured a cancer so early.
MRV Research
Prima BioMed Initiates Phase I Melanoma Study in Australia
Prima BioMed Ltd a leading immuno-oncology company, is pleased to announce the initiation of the first clinical trial site for TACTI-mel, a Phase I clinical study in melanoma using its lead compound IMP321, to be conducted in Australia.
Wider surgical margins needed for thicker primary cutaneous melanoma
A narrow excision margin appeared to increase risk for melanoma-specific death among patients with cutaneous melanoma on the trunk and/or limbs with a Breslow thickness greater than 2 mm, according to findings of a randomized, open-label multicenter trial.
This Potential First in Class Cancer Therapy Could Help Patients Avoid Eye Surgery
Uveal melanoma is a rare disease in which cancer cells form in the tissues of the eye, and comprises approximately 3% of all melanomas. It is actually the primary intraocular malignancy of the adult eye and currently, there are no effective treatments on the market for this debilitating disease.